Introduction
TP53 mutations in AML are present in 30% of R/R AML patients and are associated with poor prognosis and resistance to therapy. Earlier experiments have revealed markers of immune dysfunction in the bone marrow microenvironment of TP53m AML. However, what the role of...
Background: Liposomal cytarabine/daunorubicin (CPX-351) is a standard frontline treatment for adult patients (pts) with AML-MR. However, the pivotal trial leading to FDA-approval of CPX-351 enrolled pts aged ≥60 years (y) with: 1) therapy-related AML (t-AML), 2) AML...
The mammalian target of rapamycin (mTOR) is a serine/threonine kinase that plays a critical role in regulating cell growth, proliferation and survival. The mTOR pathway is often hyperactivated in acute myeloid leukemia (AML) and is associated with poor prognosis,...
IntroductionDespite advances in AML treatment, the persistent challenge of treatment resistance and relapse highlights the critical need for effective drug combinations to improve outcomes. Cell line-based predictions often fail clinically due to inter- and...
Context. Measurable residual disease (MRD) is a major prognostic factor in Core Binding Factor (CBF) AML (Jourdan et al. 2014, Döhner et al., 2022). Recurrent genetic alterations like KIT or FLT3 gene mutations have also shown prognostic relevance but little is known...
Recent Comments